Objective To analyze the clinical expression significance of serum interleukin-6 (IL-6), D-dimer (D-D) and procalcitonin (PCT) in mechanical ventilation patients with severe pneumonia and the value of prognosis evaluation. Methods The subjects of this study were 280 patients with mechanical ventilation and severe pneumonia who were admitted to the hospital between December 2022 and October 2024, as well as 90 healthy physical examination patients. The Kaplan-Meier method and the Cox proportional risk regression model were used to analyze patient prognosis both univariately and multivariately. Patients' prognostic information was acquired through follow-up, and the predictive value of serum IL-6, D-D, and PCT in the combination detection of mechanical ventilation in patients with severe pneumonia was studied using a receiver operating characteristic curve (ROC). Results The serum levels of IL-6, D-D, and PCT in the case group were higher than those in the healthy group. The follow-up time was 13 (7, 14) days, with 30 deaths (10.71%) among 280 patients with severe pneumonia on mechanical ventilation, and 250 survivors (89.29%), with a median overall survival (OS) time of 9 (7, 11) days. Univariate analysis results indicated that age, IL-6, D-D, PCT, and PaO2/FiO2 were all associated with poor prognosis in patients with severe pneumonia on mechanical ventilation. The results of COX multivariate regression analysis showed that age, IL-6, D-D, and PCT were independent risk factors for poor prognosis in patients with severe pneumonia on mechanical ventilation, while PaO2/FiO2 was a protective factor. The ROC curve indicated that the AUC, sensitivity, and specificity for predicting poor prognosis in patients with severe pneumonia on mechanical ventilation based on single serum indicators of IL-6, D-D, and PCT were (0.738, 0.903, 0.839; 76.7%, 86.7%, 83.3%; 70.4%, 74.0%, 72.8%), all of which were lower than those obtained by combined prediction of the three indicators with AUC and sensitivity (0.955, 96.7%, 89.2%). Conclusion Cox proportional risk model analysis showed that serum IL-6, D-D and PCT were prognostic indicators for patients with severe pneumonia. The expression of serum IL-6, D-D and PCT is increased in patients with severe pneumonia with mechanical ventilation, which is closely related to the severity of the disease, and the combined detection is of great value in the prognosis assessment.
Key words
severe pneumonia /
mechanical ventilation /
interleukin-6 /
D-dimer /
procalcitonin /
prognostic value
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 顾文惠, 叶艳萍, 肖琴. 重症肺炎患者血清NF-κB、CD64、IL-6、IL-10表达及预后评估价值[J]. 临床肺科杂志, 2023, 28(2): 211-215, 220.
[2] 王凡, 陈旭昕, 韩志海. 重症肺炎早期患者外周血T淋巴细胞亚群比例变化及预后预测效能[J]. 山东医药, 2021, 61(27): 32-36.
[3] DE BENEDICTIS FM, KEREM E, CHANG AB, et al.Complicated pneumonia in children[J]. Lancet, 2020, 396(10253): 786-798.
[4] VAUGHN VM, DICKSON RP, HOROWITZ JK, et al.Community-Acquired Pneumonia: A Review[J]. JAMA, 2024, 332(15): 1282-1295.
[5] 李敏. 重症肺炎患者中性粒细胞/淋巴细胞比值和红细胞分布宽度及其28d死亡风险的预测价值[J]. 湖南师范大学学报(医学版), 2021, 18(4): 255-258.
[6] LEE KL, LEE CM, YANG TL, et al.Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010-2019[J]. J Formos Med Assoc, 2021, 120(1): 281-291.
[7] 中国医师协会急诊医师分会. 中国急诊重症肺炎临床实践专家共识[J]. 中国急救医学, 2016, 36(2): 97-107.
[8] OLIVEIRA E SILVA PG, CERQUEIRA BATISTA FILHO LA, ISMAEL PF, et al. Community-acquired pneumonia: Epidemiology, diagnosis, prognostic severity scales, and new therapeutic options[J]. Medwave, 2023, 23(11): e2719.
[9] 郑艳霞, 陈金, 王艳莉. 血浆D二聚体联合PSI评分对重症肺炎患者预后的评估价值分析[J]. 血栓与止血学, 2021, 27(6): 968-969.
[10] 吴建, 刘融星, 陈晓玲, 等. 老年重症肺炎患者医院感染的相关因素及防控策略分析[J]. 湖南师范大学学报(医学版), 2022, 19(6): 88-91.
[11] RUEDA ZV, AGUILAR Y, MAYA MA, et al.Etiology and the challenge of diagnostic testing of community-acquired pneumonia in children and adolescents[J]. BMC Pediatr, 2022, 22(1): 169.
[12] ZHANG P, LIU B, ZHANG S, et al.Clinical application of targeted next-generation sequencing in severe pneumonia: a retrospective review[J]. Crit Care, 2024, 28(1): 225.
[13] 张阳, 郑庆凯, 陈苗, 等. 重症肺炎患者外泌体HMGB1/RAGE/NF-κB基因表达及其与病情进展的关系[J]. 中华医院感染学杂志, 2023, 33(6): 816-820.
[14] PÓVOA P, COELHO L, SALLUH J. When should we use corticosteroids in severe community-acquired pneumonia[J]. Curr Opin Infect Dis, 2021, 34(2): 169-174.
[15] YANG S, LU S, GUO Y, et al.A comparative study of general and severe mycoplasma pneumoniae pneumonia in children[J]. BMC Infect Dis, 2024, 24(1): 449.
[16] DING G, ZHANG X, VINTURACHE A, et al.Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia[J]. Eur J Pediatr, 2024, 183(7): 3001-3011.
[17] CHEN YC, HSU WY, CHANG TH.Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia[J]. Emerg Infect Dis, 2020, 26(7): 1382-1391.
[18] SENTER J, WAGNER K, GABRYSZEWSKI SJ, et al.Severe Pneumonia in a Previously Healthy Infant[J]. Clin Pediatr (Phila), 2023, 62(12): 1595-1598.
[19] LUO XQ, LUO J, WANG CJ, et al.Clinical features of severe Mycoplasma pneumoniae pneumonia with pulmonary complications in childhood: A retrospective study[J]. Pediatr Pulmonol, 2023, 58(10): 2815-2822.
[20] SHARMA PK, VINAYAK N, AGGARWAL GK, et al.Severe Necrotizing Pneumonia in Children: A Challenge to Intensive Care Specialist[J]. J Trop Pediatr, 2020, 66(6): 637-644.
PDF(2263 KB)
